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Most natural IgM antibodies are encoded by germline Ig sequences and are produced 
in large quantities by both mice and humans in the absence of intentional immuniza-
tion. Natural IgM are reactive with many conserved epitopes, including those shared 
by microorganisms and autoantigens. As a result, these antibodies play important 
roles in clearing intruding pathogens, as well as apoptotic/necrotic cells and otherwise 
damaged tissues. While natural IgM binds to target structures with low affinity due to a 
lack of significant selection by somatic hypermutation, its pentameric structure with 10 
antigen-binding sites enables these antibodies to bind multivalent target antigens with 
high avidity. Opsonization of antigen complexed with IgM is mediated by cell surface 
Fc receptors. While the existence of Fc alpha/mu receptor has been known for some 
time, only recently has the Fc receptor specific for IgM (FCMR) been identified. In this 
review, we focus on our current understandings of how natural IgM and FCMR regulate 
the immune system and maintain homeostasis under physiological and pathological 
conditions.
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iNTRODUCTiON
Studies of IgG antibodies produced in response to foreign antigens have provided a wealth of infor-
mation about the mechanisms involved in generating a seemingly limitless array of antigen-binding 
specificities by diversification of their antigen-binding domains through somatic recombination and 
mutation. In addition, a large number of investigations have shown that the effector functions of 
these antibodies are mediated through the interactions of their Fc domains with a series of isotype-
restricted receptors expressed on a variety of hematopoietic cell types.
An Fc receptor specific for IgM, now termed FCMR (1), was defined only 8 years ago. Importantly, 
and in contrast to most secreted IgG antibodies, secreted IgM (sIgM) can be subdivided into natural 
and immune IgM. Natural IgM is found at equivalent levels in sera of normal and germ-free mice, 
and it is thought that exposure to natural antigens is responsible for its production. In addition, 
natural IgM is often polyreactive, whereas immune IgM is selected for antigen-specificity and is 
usually produced following exposure to pathogens. Because it is impossible to separate the effects of 
natural IgM from immune IgM when we evaluate the consequences of interactions between FCMR 
and an IgM molecule in non-immunized individuals; in this review, serum sIgM is taken to be 
synonymous to natural IgM.
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Over the last several years, advances in understanding the 
various functions of sIgM and its interactions with FCMR have 
been accelerated by the generation of knockout mice that lack 
sIgM or FCMR. The purpose of this review is to describe new 
aspects of the nature and functions of the sIgM–FCMR axis.
NATURAL igM, AN OveRview
sIgM exists in all vertebrate species including fishes, amphibians, 
reptiles, birds, and mammals (2). Both mice and humans have 
large quantities of circulating sIgM (300–800  μg/ml for mice 
and 400–2300 μg/ml for humans). The serum levels of sIgM are 
maintained similarly in mice that are raised in pathogen-free, 
germ-free, or chemically defined antigen-free environments 
indicating that endogenous stimuli are responsible for its pro-
duction (3, 4). The cellular origin of sIgM has been postulated 
to be predominantly B-1 cells found in the peritoneal cavity (5). 
However, this view has recently been revised by evidence that 
B-1 cells residing in the spleen and bone marrow are significant 
producers of sIgM (6). Other cell types including marginal zone 
B cells have also been implicated in the production of natural 
IgM (7). B-1 cells, particularly the CD5+ B-1a subset, belong to a 
stable population maintained by self-renewal independent of gut 
microbiomes (8, 9). B-1a cells, especially the PC1lo subset (10), 
constantly migrate out of the peritoneum with some migrating 
to the spleen where they undergo activation and secret sIgM. In 
addition, the bone marrow is found to host a small number of 
CD5− plasma cells originating from the peritoneum that likely 
contribute to long-term sIgM production (11). A thorough 
discussion of natural antibody-producing cells can be found in a 
recent elegant review (12).
Polyreactivity and autoreactivity are two prominent features 
found within the sIgM population. Prior studies with monoclonal 
natural antibodies including IgM and IgG isotypes demonstrated 
that a single natural IgM or IgG is capable of binding more than 
three apparently structurally unrelated antigens (13–15). Based 
on immunoadsorption experiments or immunoblotting using 
a panel of self-antigens, it has been estimated that 5–100% of 
normal mouse or human sera is autoreactive [Reviewed in Ref. 
(16)]. These properties of sIgM have been attributed to the ger-
mline configuration of their V region structures, characterized by 
enrichment of positively charged amino acids, especially arginine 
(17, 18). Also, compared to induced IgM antibodies, the V regions 
of sIgM have relatively higher frequencies of tyrosine and serine 
residues, which bear side-chain hydroxyl groups, allowing sIgM 
to bind various epitopes via ionic and hydrogen bonding (17, 
18). These interactions, however, are usually of low affinity (19). 
Nevertheless, the polymeric binding between pentameric sIgM 
and a target antigen reaches a functional affinity (avidity) much 
higher than the intrinsic affinity (20, 21). By using the surface 
plasmon resonance technique to determine binding avidities, 
Diaw et  al. analyzed five monoclonal sIgM against dissimilar 
autoantigens including cytoskeletal antigens and DNA. The 
kinetic binding constants of all five sIgM were indistinguishable 
from those observed for immune antibodies (22).
The biological functions of sIgM have been described to 
include removal of apoptotic cells, protection from infection, 
and tissue homeostasis (16, 23). The third function is attributed 
to sIgM-mediated clearance of tissue-breakdown molecules and 
binding to cell surface molecules on B and T cells to inhibit cell 
division and/or activation, thereby minimizing inflammation 
(16). This immunomodulatory role of sIgM has been confirmed 
by studies with two independently genetically engineered mouse 
strains lacking serum IgM (Sμ−/−) (24, 25). These mice exhibit 
abnormal B cell development, impaired antibody responses, and 
enhanced production of autoantibodies (see below).
THe igM Fc ReCePTOR, FCMR
Originally identified and termed as TOSO [encoded by Fas 
apoptosis inhibitory molecule 3 (FAIM3)] in 1998 (26), FCMR 
was recently rediscovered and characterized as an IgM-specific 
Fc receptor (27, 28). A consensus nomenclature for this molecule 
has recently been proposed as FCMR (1). FCMR is a transmem-
brane protein with a predicted molecular weight of ~41 KDa, but 
with heavily O-linked glycosylation in the extracellular domain, a 
mature molecule can reach ~60 KDa (26, 27, 29). The extracellu-
lar domain contains a single Ig-like domain with binding activity 
to the IgM Fc region, while the intracellular domain contains 
tyrosine residues that serve as phosphorylation sites to initiate/
mediate signaling cascades. A thorough review of the molecular 
features of FCMR has recently been published (30).
To date, most of our understanding of the functions of FCMR 
comes from studies of FCMR-deficient mice. Natural mutations 
of FCMR in humans have not been reported. There are three 
independently generated Fcmr gene knockout strains have been 
reported (31–34) and two of them were characterized in detail 
(31, 32, 34) (Table 1). Clear differences exist among these mice, 
possibly due to the nature of gene targeting strategies, differ-
ing involvement of 129/Sv ES cells, extent of backcrossing to 
the B6 background, and husbandry environment. Readers are 
reminded of a recent report that revealed an astonishing “side 
effect” of passenger mutations of the 129 line that persists even 
after extensive backcrossing (35). This finding could explain why 
distinct knockout strains for the same gene often yield discrepant 
functional results.
eXPReSSiON OF FCMR
The expression of FCMR in different cell types has been investi-
gated at both the mRNA and protein levels by a number of inves-
tigators without complete agreement. The ImmGen database, a 
microarray-based public resource of mouse transcript expression 
(www.immgen.org), indicates a broad expression pattern of Fcmr 
among all lymphoid and myeloid cells tested, with relative expres-
sion levels ranging from ~50 in T cells, NK, DCs, myeloid, and 
stromal cells to ~5000 in B cells. Our quantitative PCR analyses 
of sorted populations revealed a similar pattern of expression, 
also with B cells expressing the highest levels (31). Northern blot 
analysis of human tissues also revealed a broad expression pattern 
of FCMR in lymphoid and non-lymphoid tissues (26, 28).
Fc receptor specific for IgM protein expression has been 
assessed in a variety of cell types using several monoclonal 
antibodies. Kubagawa and colleagues reported that FCMR 
TABLe 1 | Phenotypes of Fcmr−/− mice.
Reports by Choi et al. (31) Ouchida et al. (34) Honjo et al. (32) Nguyen et al. (33)
Strain Fcmrtm1Mak Fcmrtm1Ohno Fcmrtm1.2Khl
Genetic manipulation Deleted exons 2–8. Involving 129/Sv  
ES cells and backcrossing with C57BL/6 
mice. The Neo gene cassette was not 
deleted after recombination
Deleted exons 2–4. Involving 129/Sv ES cells and backcrossing 
with C57BL/6 mice. The Neo gene cassette was deleted after 
recombination
Deleted exons 4–7. The Neo 
gene cassette was deleted 
after recombination. Pure 
B6 background
B cells BM Small pre-B↓ Not changed Not changed NR
Immature B↓
Spleen FOB↓, MZB unchanged FOB unchanged, MZB↓, 
transitional B↑
MZB↓, B-1↑ B cells↓
PerC B-1a↑, B-2↓ Not changed Not changed NR
T cells Not changed Not changed Not changed Not changed
Basal Ig levels IgG1↓, No change for other classes IgM↑, no change for total IgG IgM↑, IgG3↑, no change for  
other classes
NR
TI responses Enhanced Reduced Phosphorylcholine-specific 
responses are enhanced
NR
TD responses Enhanced Reduced Reduced NR
Responses to infectious 
pathogens
NR NR IgM and IgG3 responses to 





Anti-ds-DNA and ANAs ↑ Anti-DNA, -rheumatoid  
factor, and ANAs ↑
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expression was restricted to human B, T, and NK cells, and 
mouse B cells (27, 32). The lack of expression of mouse FCMR 
by non-B cells was confirmed by Ohno and colleagues (28, 34). 
However, Lang et  al. using a different monoclonal antibody 
reported expression of FCMR on myeloid cells (36). On the 
other hand, Honjo et al. could not detect expression of exon 2 
mRNA of Fcmr and FCMR protein in granulocytes with their 
monoclonal antibodies (37). Analysis of FCMR expression is 
complicated by the fact that it undergoes internalization after 
binding IgM (29). Freshly isolated tonsillar B and T cells are 
negative for FCMR on the cell surface; however, these cells 
become positive for FCMR after a brief culture with IgM-
negative medium in vitro (27). Therefore, detection of FCMR 
at the cell membrane becomes problematic and ambiguous 
depending on the method used for study. In addition, future 
studies are warranted to determine whether the various anti-
FCMR monoclonal antibodies recognize the same or alternative 
forms of FCMR expressed in different tissues.
It should be recognized that FCMR, while specific for IgM, 
is not the only cell surface Fc receptor capable of binding IgM. 
The Fcα/μ receptor (FCA/MR), encoded by the FCA/MR gene in 
humans, is an unusual Fc receptor in that it binds to two different 
antibody isotypes, IgA, and IgM (38). The receptor is broadly 
expressed in humans and mice, but with significant differences 
in expression patterns between the two species, particularly on 
hematopoietic cells (39). Both IgA and IgM cross-compete for 
binding to the mouse receptor suggesting a common site of 
interaction. Pentameric IgM does not have to contain J chain to 
bind the receptor (40).
A second receptor with dual specificity for IgA and IgM is 
the polymeric immunoglobulin receptor, PIGR. This receptor 
only binds polymeric IgA and IgM associated with the J chain at 
high affinities (41). In contrast to FCA/MR and FCMR, PIGR is 
expressed only on epithelial cells (42).
SiGNALiNG POTeNTiAL OF FCMR
The intracellular domain of FCMR contains several tyrosine 
residues but lacks a commonly present immunoreceptor 
tyrosine-based activation motif (ITAM) and/or the immuno-
receptor tyrosine-based inhibition motif (ITIM) (27). However, 
the FCMR cytoplasmic tail does contain an Asp–X5–Asp–
Tyr401–Ile–Asn sequence that matches the recently identified 
immunoglobulin tail tyrosine (ITT) phosphorylation motif 
Glu/Asp–X6–7–Asp–Tyr–X–Asn present in membrane IgG 
(mIgG) and mIgE (43). This consensus motif is found to amplify 
BCR signals in class-switched memory B cells by recruiting the 
adaptor Grb2, thereby allowing switched memory B cells to 
respond more quickly and vigorously than primary B cells to 
secondary exposures to antigens (43, 44). Therefore, the ITT 
motif of FCMR could serve as a molecular platform to interact 
with and influence the BCR signaling pathway. In fact, cross 
linking FCMR with either anti-FCMR monoclonal antibodies 
or preformed IgM immune complexes induced phosphoryla-
tion of tyrosine and serine residues of FCMR in B cells (27) and 
phosphorylation of PLC-γ and Erk1/2 in NK cells (45). Our 
analyses also showed that FCMR positively modulates tonic 
BCR signaling. The basal levels of phospho-Syk in pre-B, MZ, 
and B-1a cells were lower in Fcmr−/− mice than WT controls 
(31). Ligation of FCMR alone did not affect cellular prolif-
eration and survival (34). However, BCR-induced proliferation 
and survival were reduced in the absence of FCMR (31, 34). 
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Moreover, ligation of FCMR had no effect on LPS or anti-CD40 
antibody-induced proliferation and survival (31, 34). These 
results argue that FCMR more closely approximates the activity 
of BCR than TLR or CD40 on the surface of B cells. Therefore, 
it is conceivable that FCMR plays a modulatory role in BCR 
signaling that supports survival.
THe sigM–FCMR AXiS iN ReGULATiON 
OF eARLY B CeLL DeveLOPMeNT
Early stages of B cell development are characterized by ordered 
gene expression consisting of H and L chain gene rearrangements 
in pro-B and pre-B cells, respectively. The expression of produc-
tive μH chains leads to assembly and expression of pre-BCRs on 
the surface of pre-B cells. In conjunction with the IL-7 signaling, 
pre-BCRs trigger clonal expansion for approximately six divi-
sions (46) and upregulate expression of IRF4, which promotes 
pre-B cell dissociation from stromal cells, a critical step leading 
to differentiation of small pre-B cells and L chain gene rearrange-
ment (47).
The expression levels of FCMR in early B cells gradually 
increases starting from pro-B to pre-B and to immature B cells 
(ImmGen database), similar to our assessment by qPCR (31). In 
the absence of FCMR, as noted in the Fcmrtm1Mak strain but not 
the Fcmrtm1Ohno strain (Table 1), the development of pre-B and 
immature B cells was significantly reduced (31). Remarkably, 
Sμ−/− mice lacking sIgM exhibited similar deficiencies in pre-B 
and immature B cells (31, 48). Therefore, the sIgM–FCMR axis 
may represent a positive feedback loop promoting develop-
ment and maturation of early B cells. Indeed, irradiated normal 
recipient mice receiving WT hematopoietic stem cells (HSCs) 
and sIgM-containing sera generated significantly more pre-B 
cells than recipients of WT HSCs and sIgM-deficient sera (31). 
This observation suggests that sIgM could enhance generation of 
pre-B and immature B cells in a FCMR-dependent fashion (31).
THe sigM–FCMR AXiS iN ReGULATiON 
OF LATe STAGeS OF B CeLL 
DeveLOPMeNT
Fc receptor specific for IgM deficiency in mice was associated 
with altered distributions of peripheral B cells. The Fcmrtm1Mak 
strain exhibited reduced numbers of splenic follicular B cells, 
but the numbers of MZ B cells remained unchanged (31). In 
the peritoneum, the frequencies of B-1a cells were increased 
while B-2 cells in this strain were decreased (31). In contrast, 
the Fcmrtm1Ohno strain exhibited reduced numbers of MZ B cells, 
increased transitional B cells and B-1 cells in the spleen, and no 
change in peritoneal B cells (32, 34) (Table 1). The differences 
in distribution of B cells between the two strains are also associ-
ated with differences between the strains in basal levels of serum 
immunoglobulins in naive mice (Table 1) (31, 32, 34, 48).
Our parallel assessments of Sμ−/− and Fcmrtm1Mak mice revealed 
strikingly similar changes in peripheral B cells: reduced numbers 
of FO but increased numbers of MZ B cells in the spleen, and 
increased numbers of B-1a cells but reduced B-2 cells in the 
peritoneum (31). A second Sμ−/− strain also exhibited expansion 
of MZ and B-1a cells and reduction in FO B cells (25). These 
data agree with the conclusion that the sIgM–FCMR axis may 
promote FO B cell development. Regarding B-1 cells, Nguyen 
et al. recently reported that peritoneal CD5+ B cells in Sμ−/− mice 
were not “regular” B-1a cells but exhibited characteristics of 
“anergic” B cells (48). They further showed that the lack of sIgM 
in Sμ−/− mice not only altered B cell numbers (reduced FO and 
expanded MZ B cells), confirming our analyses (31), but also 
fundamentally altered the B cell repertoire (the usage of VH genes) 
and selection (48). More importantly, administration of sIgM into 
Sμ−/− mice reversed the MZ/FO B cell ratio and mostly restored 
normal B cell development (48, 49). These results strongly suggest 
that the sIgM–FCMR axis does indeed modulate differentiation 
of peripheral B cells.
THe sigM–FCMR AXiS iN ReGULATiON 
OF T-iNDePeNDeNT iMMUNe 
ReSPONSeS
Immunization of the Fcmrtm1Mak strain with NP-LPS stimulated 
increased levels of plasma cell development and secretion of 
IgM antibodies (31). This data can be explained by increased 
numbers of peritoneal B-1a cells in Fcmr−/− mice as B-1a cells 
are the primary responders to NP-LPS challenge in this set-
ting (31). Immunization of Fcmrtm1Mak mice with NP-FICOLL, 
which predominantly activates MZ B cells, resulted in moderate 
increases in plasma cells without a significant increase in sIgM, 
which seems to correlate with relatively normal numbers of MZ 
B cells in this strain (31). In contrast, studies of the Fcmrtm1Ohno 
strain yielded opposing results, i.e., reduced production of sIgM 
and IgG following NP-FICOLL immunization (34) (Table  1). 
This discrepancy could be due to the fact that the MZ B cell 
compartment is reduced in the Fcmrtm1Ohno strain but remains 
unchanged (if not slightly expanded) in the Fcmrtm1Mak strain. By 
using a complicated antigen, Streptococcus pneumoniae (R36A), 
Honjo et  al. showed increased IgM and IgG3 responses to the 
carbohydrate phosphorylcholine (PC), epitope of the pathogen, 
in Fcmrtm1Ohno mice (32).
Previous studies in Sμ−/− mice revealed enhanced production 
of IgG2a antibodies following immunization with NP-FICOLL 
(50). Similar findings were reported in another Sμ−/− strain (25). 
Taken together, these results suggest that the sIgM–FCMR path-
way may negatively regulate TI immune responses likely through 
modulating the sensitivity of responding B cells.
THe sigM–FCMR AXiS iN ReGULATiON 
OF T-DePeNDeNT iMMUNe ReSPONSeS
Studies of TD immune responses in Fcmrtm1Ohno and Fcmrtm1Mak 
mice have also yielded conflicting results. Our analyses in 
the Fcmrtm1Mak strain revealed a moderate increase in primary 
IgM but not of IgG2b responses following immunization with 
NP-KLH/alum (31). During a recall immune response, FCMR-
deficient mice produced significantly more germinal centers and 
plasma cells but only exhibited subtle differences in overall serum 
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antibody levels (31). In contrast, following a similar immuniza-
tion protocol, Ouchida et al. and Honjo et al. reported that the 
Fcmrtm1Ohno mice developed generally decreased TD immune 
responses (32, 34) (Table  1). Given the fact that the antibody 
responses elicited in both strains were relatively moderate, we 
believe that the role of FCMR in TD immune responses may be 
limited.
Previous studies of Sμ−/− mice indicated that sIgM is required 
to elicit optimal TD immune responses because in the absence 
of sIgM, Sμ−/− mice produced significantly lower levels of IgG1 
anti-NP antibodies, and antibody affinity maturation was also 
delayed (25). However, injection of sIgM into Sμ−/− mice before 
immunization increased NP-specific IgG1 responses (25). These 
results suggest that sIgM could augment TD humoral responses, 
but whether this was mediated by sIgM-mediated antigen pro-
cessing/presentation, or FCMR-mediated signaling that renders 
B cells hyperresponsive to activation signals, or both, remains to 
be determined.
THe sigM–FCMR AXiS SUPPReSSeS 
DeveLOPMeNT OF AUTOiMMUNiTY
Spontaneous production of increased levels of autoreactive 
antibodies, including anti-DNA and anti-nuclear antibodies, was 
detected in both FCMR-deficient strains (Table 1). Surprisingly, 
the existence of these autoantibodies in FCMR-deficient mice 
was insufficient to induce pathology, e.g., glomerular damage 
common to lupus-like diseases. Introducing Fcmr deficiency onto 
the autoimmune-prone B6.MRL Faslpr/lpr background accelerated 
development of autoreactive antibodies but still had no effect on 
severity of renal pathology and function or overall survival (51). 
These results suggest that FCMR acts to inhibit activation of non-
pathogenic autoreactive B cells.
Absence of sIgM in Sμ−/− mice was also associated with accel-
erated development of IgG autoantibodies (48, 52, 53). Similar 
to FCMR-deficient mice, both Sμ−/− strains spontaneously gener-
ated IgG anti-DNA autoantibodies (52, 53). Immune complex 
deposition in the kidneys was observed in a small proportion 
of mice (53). When Sμ−/− mice were bred to MRLlpr/lpr mice, the 
progeny exhibited accelerated development of IgG autoantibod-
ies and autoimmune disease (52). Moreover, adoptive transfer of 
Sμ−/− BM cells into recipient mice containing normal levels of 
sIgM abrogated anti-nuclear antibody development (48). Thus, 
sIgM and FCMR may negatively regulate autoimmunity through 
the sIgM–FCMR pathway not withstanding that sIgM may also 
modulate autoimmune responses through FCMR-independent 
mechanisms, such as complement fixation, immune complex 
uptake, and antigen presentation (23).
In addition to the functions of FCMR in the above lupus 
model, Lang et al. studied the roles of FCMR in an experimental 
autoimmune encephalomyelitis (EAE) model and demonstrated 
that Fcmrtm1Mak mice were resistant to EAE (54). While changes 
in expression of IL-17 in T cells were not observed in this report 
(54), a more recent study using single cell RNA-sequencing in 
isolated Th17 cells identified a strong correlation between expres-
sion of FCMR and the Th17 cytokine signature (55). Indeed, 
FCMR-deficient T cells fail to produce IL-17A upon stimulation 
(55). IL-17A is a critical driving cytokine for EAE (56). Thus, 
FCMR may promote pathogenesis of Th17-mediated diseases.
DOeS FCMR PLAY A ROLe iN 
CONTROLLiNG iNFeCTiON?
While sIgM has long been postulated to play an important role 
as first line in defense against infectious agents (2), there are also 
indications that FCMR may play a role during inflammatory 
responses to infection. Honjo et al. immunized Fcmrtm1Ohno mice 
with a live attenuated strain of S. pneumoniae (R36A) to examine 
antigen-specific immune responses against the bacterial PC and 
protein determinants (32). While the FCMR-deficient mice suc-
cessfully elicited anti-PC antibody responses, they failed to gen-
erate anti-protein antibody responses (32). This result suggests 
that FCMR has discrete roles in B cells (possibly coupled with 
specificity of the BCR) in responding to protein and non-protein 
determinants of live pathogens.
Lang et al. performed wide range analyses of the Fcmrtm1Mak 
strain infected with Listeria (36). FCMR-deficient mice were 
resistant to LPS-induced septic shock and failed to control 
Listeria infection. This phenotype is associated with decreased 
systemic production of IFN-γ, IL-12, and IL-6 in FCMR-
deficient mice (36). While most of the changes in this model 
were attributed to absence of FCMR in phagocytes, including 
monocytes, macrophages, and granulocytes (36), the expres-
sion of FCMR by these myeloid cells was questioned by Honjo 
et al. who failed to detect expression of exon 2 of Fcmr by PCR 
and protein by FACS in granulocytes (37). More recently, Lang 
et al. have reported that FCMR is required for development and 
function of inflammatory dendritic cells (iDCs) (57). FCMR 
mutant mice were deficient for iDCs in the liver and thereby 
failed to recruit and activate CD8+ T cells to clear lymphocytic 
choriomeningitis virus (57). Because the expression levels of 
FCMR transcripts in granulocytes and DCs are about 100-
fold lower than in B cells (ImmGen database) and it remains 
unknown whether infection could upregulate expression of 
FCMR in granulocytes and DCs, future studies are warranted to 
determine the molecular mechanisms of FCMR action in non-B 
cells in response to infection.
CONCLUDiNG ReMARKS
It is becoming broadly accepted that sIgM has protective func-
tions in defense against infection and is important for maintain-
ing tissue homeostasis. Earlier studies have revealed that sIgM 
binds to infectious agents, as well as altered self-antigens, and 
that sIgM-antigen complexes activate the complement cascade 
and initiate inflammatory responses. The recent identification of 
FCMR has provided new insights into the mechanisms of sIgM 
function in vivo. While evidence of the beneficial effects of sIgM 
on survival have dominated the literature, it is worth noting 
that sIgM can also play pathogenic roles under certain circum-
stances. For example, natural IgM is critical for development of 
inflammation and damage in a model of ischemia–reperfusion 
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injury (58–61). In this case, sIgM binds to damaged tissue and 
activates the complement cascade causing massive inflammatory 
responses. Blocking sIgM binding to modified self-antigens with 
an anti-annexin IV single-chain antibody (scFv) significantly 
reduced graft inflammation and injury (58). Recently, Panzer 
et al. reported that injection of sIgM into B-cell-deficient μMT 
mice induced albuminuria in a complement-induced glomerular 
disease model (62). These observations raise a note of caution 
regarding postulated application of intravenous IgM (IVIgM) 
(63), a homolog of intravenous IgG (IVIg), to the treatment of 
autoimmune and inflammatory diseases. More recently, Brenner 
et  al. reported that a FCMR-Fc fusion protein comprising the 
extracellular domain of FCMR exhibited therapeutic effects by 
inhibiting MOG-induced neuroinflammatory responses in an 
EAE model (54). An anti-FCMR monoclonal antibody has also 
been shown to be beneficial in experimental malaria infection 
(64). Future studies are warranted to determine whether blockade 
of FCMR could be a therapeutic approach to treat autoimmune 
and inflammatory diseases.
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